# Humane Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/humane-genomics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.humanegenomics.com
- Total disclosed funding: $0.1M
- Latest round: Seed (Feb 12, 2025)
- Investors on record: 2

## About

Based in New York, US, and founded in 2019 by CEO Peter Weijmarshausen, Chad Moles, and Andrew Hessel, Humane Genomics Inc operates as a biotechnology company that focuses on the development of a virus development platform that develops artificial viruses to cure diseases. In February 2025, Humane Genomics Inc raised an undisclosed amount of seed funding led by new investor Union Square Ventures. The company develops precision-designed oncolytic viral therapies, utilizing synthetic biology to engineer viruses that can effectively kill cancer cells. Using DNA synthesis and lab robotics, the company's platform creates an oncolytic virus that is customized for various tumor types using a proprietary design and digital library. This allows patients to receive safe and effective therapies for cancer cells taken from their biopsy. In addition, the technology used by the company can 3D print or synthesize DNA based on a computer file. The company will use the February 2025 funding to support its expansion plans.

## Funding rounds

- Seed, Feb 12, 2025 — Union Square Ventures
- Seed, Aug 27, 2021, $0.1M — Y Combinator

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Union Square Ventures (https://capitalatlas.ai/funds/union-square-ventures) — Seed